Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 3
2015 3
2016 1
2018 1
2019 2
2021 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Showing results for michel p. R. Gordon
Your search for Micheil P. R. Gordon retrieved no results
Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.
Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, van Veldhuisen DJ, Zannad F, Zile MR, Desai AS, Claggett B, Jhund PS, Boytsov SA, Comin-Colet J, Cleland J, Düngen HD, Goncalvesova E, Katova T, Kerr Saraiva JF, Lelonek M, Merkely B, Senni M, Shah SJ, Zhou J, Rizkala AR, Gong J, Shi VC, Lefkowitz MP; PARAGON-HF Investigators and Committees. Solomon SD, et al. N Engl J Med. 2019 Oct 24;381(17):1609-1620. doi: 10.1056/NEJMoa1908655. Epub 2019 Sep 1. N Engl J Med. 2019. PMID: 31475794 Free article. Clinical Trial.
RESULTS: There were 894 primary events in 526 patients in the sacubitril-valsartan group and 1009 primary events in 557 patients in the valsartan group (rate ratio, 0.87; 95% confidence interval [CI], 0.75 to 1.01; P = 0.06). The incidence of death from cardiovascular caus …
RESULTS: There were 894 primary events in 526 patients in the sacubitril-valsartan group and 1009 primary events in 557 patients in the vals …
Benralizumab for the Prevention of COPD Exacerbations.
Criner GJ, Celli BR, Brightling CE, Agusti A, Papi A, Singh D, Sin DD, Vogelmeier CF, Sciurba FC, Bafadhel M, Backer V, Kato M, Ramírez-Venegas A, Wei YF, Bjermer L, Shih VH, Jison M, O'Quinn S, Makulova N, Newbold P, Goldman M, Martin UJ; GALATHEA Study Investigators; TERRANOVA Study Investigators. Criner GJ, et al. N Engl J Med. 2019 Sep 12;381(11):1023-1034. doi: 10.1056/NEJMoa1905248. Epub 2019 May 20. N Engl J Med. 2019. PMID: 31112385 Clinical Trial.
RESULTS: In GALATHEA, the estimates of the annualized exacerbation rate were 1.19 per year (95% confidence interval [CI], 1.04 to 1.36) in the 30-mg benralizumab group, 1.03 per year (95% CI, 0.90 to 1.19) in the 100-mg benralizumab group, and 1.24 per year (95% CI, 1.08 to 1.42) …
RESULTS: In GALATHEA, the estimates of the annualized exacerbation rate were 1.19 per year (95% confidence interval [CI], 1.04 to 1.36) in t …
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Johnston SC, Easton JD, Farrant M, Barsan W, Conwit RA, Elm JJ, Kim AS, Lindblad AS, Palesch YY; Clinical Research Collaboration, Neurological Emergencies Treatment Trials Network, and the POINT Investigators. Johnston SC, et al. N Engl J Med. 2018 Jul 19;379(3):215-225. doi: 10.1056/NEJMoa1800410. Epub 2018 May 16. N Engl J Med. 2018. PMID: 29766750 Free PMC article. Clinical Trial.
Major ischemic events occurred in 121 of 2432 patients (5.0%) receiving clopidogrel plus aspirin and in 160 of 2449 patients (6.5%) receiving aspirin plus placebo (hazard ratio, 0.75; 95% confidence interval [CI], 0.59 to 0.95; P=0.02), with most events occurring during th …
Major ischemic events occurred in 121 of 2432 patients (5.0%) receiving clopidogrel plus aspirin and in 160 of 2449 patients (6.5%) receivin …
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, Campbell SE, Oshima R, Amarenco P, Blom DJ, Brinton EA, Eckel RH, Elam MB, Felicio JS, Ginsberg HN, Goudev A, Ishibashi S, Joseph J, Kodama T, Koenig W, Leiter LA, Lorenzatti AJ, Mankovsky B, Marx N, Nordestgaard BG, Páll D, Ray KK, Santos RD, Soran H, Susekov A, Tendera M, Yokote K, Paynter NP, Buring JE, Libby P, Ridker PM; PROMINENT Investigators. Das Pradhan A, et al. N Engl J Med. 2022 Nov 24;387(21):1923-1934. doi: 10.1056/NEJMoa2210645. Epub 2022 Nov 5. N Engl J Med. 2022. PMID: 36342113 Clinical Trial.
Long-term use of ticagrelor in patients with prior myocardial infarction.
Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Oude Ophuis T, Budaj A, Theroux P, Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, Murphy SA, Wiviott SD, Held P, Braunwald E, Sabatine MS; PEGASUS-TIMI 54 Steering Committee and Investigators. Bonaca MP, et al. N Engl J Med. 2015 May 7;372(19):1791-800. doi: 10.1056/NEJMoa1500857. Epub 2015 Mar 14. N Engl J Med. 2015. PMID: 25773268 Free article. Clinical Trial.
RESULTS: The two ticagrelor doses each reduced, as compared with placebo, the rate of the primary efficacy end point, with Kaplan-Meier rates at 3 years of 7.85% in the group that received 90 mg of ticagrelor twice daily, 7.77% in the group that received 60 mg of ticagrelor twice …
RESULTS: The two ticagrelor doses each reduced, as compared with placebo, the rate of the primary efficacy end point, with Kaplan-Meier rate …
Prospects for Observing and Localizing Gravitational-Wave Transients with Advanced LIGO and Advanced Virgo.
Abbott BP; LIGO Scientific Collaboration; Virgo Collaboration; Abbott R, Abbott TD, Abernathy MR, Acernese F, Ackley K, Adams C, Adams T, Addesso P, Adhikari RX, Adya VB, Affeldt C, Agathos M, Agatsuma K, Aggarwal N, Aguiar OD, Ain A, Ajith P, Allen B, Allocca A, Altin PA, Amariutei DV, Anderson SB, Anderson WG, Arai K, Araya MC, Arceneaux CC, Areeda JS, Arnaud N, Arun KG, Ashton G, Ast M, Aston SM, Astone P, Aufmuth P, Aulbert C, Babak S, Baker PT, Baldaccini F, Ballardin G, Ballmer SW, Barayoga JC, Barclay SE, Barish BC, Barker D, Barone F, Barr B, Barsotti L, Barsuglia M, Barta D, Bartlett J, Bartos I, Bassiri R, Basti A, Batch JC, Baune C, Bavigadda V, Bazzan M, Behnke B, Bejger M, Belczynski C, Bell AS, Bell CJ, Berger BK, Bergman J, Bergmann G, Berry CP, Bersanetti D, Bertolini A, Betzwieser J, Bhagwat S, Bhandare R, Bilenko IA, Billingsley G, Birch J, Birney R, Biscans S, Bisht A, Bitossi M, Biwer C, Bizouard MA, Blackburn JK, Blair CD, Blair D, Blair RM, Bloemen S, Bock O, Bodiya TP, Boer M, Bogaert G, Bogan C, Bohe A, Bojtos P, Bond C, Bondu F, Bonnand R, Bork R, Boschi V, Bose S, Bozzi A, Bradaschia C, Brady PR, Braginsky VB, Branchesi M, Brau JE, Briant T, Brillet A, Br… See abstract for full author list ➔ Abbott BP, et al. Living Rev Relativ. 2016;19(1):1. doi: 10.1007/lrr-2016-1. Epub 2016 Feb 8. Living Rev Relativ. 2016. PMID: 28179853 Free PMC article. Review.
Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease.
Ellis SG, Kereiakes DJ, Metzger DC, Caputo RP, Rizik DG, Teirstein PS, Litt MR, Kini A, Kabour A, Marx SO, Popma JJ, McGreevy R, Zhang Z, Simonton C, Stone GW; ABSORB III Investigators. Ellis SG, et al. N Engl J Med. 2015 Nov 12;373(20):1905-15. doi: 10.1056/NEJMoa1509038. Epub 2015 Oct 12. N Engl J Med. 2015. PMID: 26457558 Free article. Clinical Trial.
RESULTS: Target-lesion failure at 1 year occurred in 7.8% of patients in the Absorb group and in 6.1% of patients in the Xience group (difference, 1.7 percentage points; 95% confidence interval, -0.5 to 3.9; P=0.007 for noninferiority and P=0.16 for superiority). Th …
RESULTS: Target-lesion failure at 1 year occurred in 7.8% of patients in the Absorb group and in 6.1% of patients in the Xience group (diffe …
The future is now: model-based clinical trial design for Alzheimer's disease.
Romero K, Ito K, Rogers JA, Polhamus D, Qiu R, Stephenson D, Mohs R, Lalonde R, Sinha V, Wang Y, Brown D, Isaac M, Vamvakas S, Hemmings R, Pani L, Bain LJ, Corrigan B; Alzheimer's Disease Neuroimaging Initiative; Coalition Against Major Diseases. Romero K, et al. Clin Pharmacol Ther. 2015 Mar;97(3):210-4. doi: 10.1002/cpt.16. Epub 2014 Dec 27. Clin Pharmacol Ther. 2015. PMID: 25669145 Free PMC article.
Impact of centre volume, surgeon volume, surgeon experience and geographic location on reoperation after intramedullary nailing of tibial shaft fractures.
Swiontkowski M, Teague D, Sprague S, Bzovsky S, Heels-Ansdell D, Bhandari M, Schemitsch EH, Sanders DW, Tornetta P, Walter SD; SPRINT Investigators. Swiontkowski M, et al. Can J Surg. 2021 Jul 5;64(4):E371-E376. doi: 10.1503/cjs.004020. Can J Surg. 2021. PMID: 34222771 Free PMC article. Clinical Trial.
RESULTS: There were no significant differences in the odds of reoperation between high- and low-volume centres (p = 0.9). Overall, surgeon volume significantly affected the odds of reoperation (p = 0.03). ...
RESULTS: There were no significant differences in the odds of reoperation between high- and low-volume centres (p = 0.9). Overall, su …
Constraints on cosmic strings from the LIGO-Virgo gravitational-wave detectors.
Aasi J, Abadie J, Abbott BP, Abbott R, Abbott T, Abernathy MR, Accadia T, Acernese F, Adams C, Adams T, Adhikari RX, Affeldt C, Agathos M, Aggarwal N, Aguiar OD, Ajith P, Allen B, Allocca A, Amador Ceron E, Amariutei D, Anderson RA, Anderson SB, Anderson WG, Arai K, Araya MC, Arceneaux C, Areeda J, Ast S, Aston SM, Astone P, Aufmuth P, Aulbert C, Austin L, Aylott BE, Babak S, Baker PT, Ballardin G, Ballmer SW, Barayoga JC, Barker D, Barnum SH, Barone F, Barr B, Barsotti L, Barsuglia M, Barton MA, Bartos I, Bassiri R, Basti A, Batch J, Bauchrowitz J, Bauer TS, Bebronne M, Behnke B, Bejger M, Beker MG, Bell AS, Bell C, Belopolski I, Bergmann G, Berliner JM, Bersanetti D, Bertolini A, Bessis D, Betzwieser J, Beyersdorf PT, Bhadbhade T, Bilenko IA, Billingsley G, Birch J, Bitossi M, Bizouard MA, Black E, Blackburn JK, Blackburn L, Blair D, Blom M, Bock O, Bodiya TP, Boer M, Bogan C, Bond C, Bondu F, Bonelli L, Bonnand R, Bork R, Born M, Boschi V, Bose S, Bosi L, Bowers J, Bradaschia C, Brady PR, Braginsky VB, Branchesi M, Brannen CA, Brau JE, Breyer J, Briant T, Bridges DO, Brillet A, Brinkmann M, Brisson V, Britzger M, Brooks AF, Brown DA, Brown DD, Brückner F, Bulik T, Bulten HJ, Bu… See abstract for full author list ➔ Aasi J, et al. Phys Rev Lett. 2014 Apr 4;112(13):131101. doi: 10.1103/PhysRevLett.112.131101. Epub 2014 Apr 4. Phys Rev Lett. 2014. PMID: 24745400 Free article.
11 results